These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists]. Dominiak P; Zidek W MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703 [No Abstract] [Full Text] [Related]
3. [What are the consequences of the LIFE Study for general practice]. Zidek W MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704 [No Abstract] [Full Text] [Related]
4. [Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard]. MMW Fortschr Med; 2002 May; 144(20):60-1. PubMed ID: 12119887 [No Abstract] [Full Text] [Related]
5. [Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker]. MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813983 [No Abstract] [Full Text] [Related]
6. [Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved]. Einecke D MMW Fortschr Med; 2002 Apr; 144(14):4-5. PubMed ID: 12014276 [No Abstract] [Full Text] [Related]
8. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679 [TBL] [Abstract][Full Text] [Related]
9. [Results from the LIFE study: promising effects of new hypertensive agents]. Nilsson P; Kahan T Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477 [No Abstract] [Full Text] [Related]
10. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193 [No Abstract] [Full Text] [Related]
11. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. Fossum E; Moan A; Kjeldsen SE; Devereux RB; Julius S; Snapinn SM; Edelman JM; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Dahlöf B; J Am Coll Cardiol; 2005 Sep; 46(5):770-5. PubMed ID: 16139123 [TBL] [Abstract][Full Text] [Related]
12. Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE. Diabet Med; 2002 Sep; 19 Suppl 5():6. PubMed ID: 12207800 [No Abstract] [Full Text] [Related]
13. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615 [TBL] [Abstract][Full Text] [Related]
14. [Losartan in isolated systolic hypertension--convincing results of a LIFE sub-group study]. MMW Fortschr Med; 2003 Jan; 145(1-2):50-1. PubMed ID: 12638440 [No Abstract] [Full Text] [Related]
15. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614 [TBL] [Abstract][Full Text] [Related]
17. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Devereux RB; Dahlöf B Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective]. de Boer RA; van Veldhuisen DJ; Gans RO; Gansevoort RT Ned Tijdschr Geneeskd; 2003 Jan; 147(3):96-9. PubMed ID: 12577767 [TBL] [Abstract][Full Text] [Related]
19. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428 [TBL] [Abstract][Full Text] [Related]
20. The LIFE Trial in 2004. Beevers DG J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931 [No Abstract] [Full Text] [Related] [Next] [New Search]